+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4763052
  • Report
  • Region: Global
  • 102 pages
  • IMARC Group
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Cipla Limited
  • Emcure
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Mylan
  • MORE
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.

Market Summary:

Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.

On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Key Questions Answered in This Report:
  • How has the global HIV drugs market performed so far and how will it perform in the coming years?
  • What are the key regions in the global HIV drugs market?
  • Which are the popular class types in the global HIV drugs market?
  • What are the major distribution channels in the global HIV drugs market?
  • What are the various stages in the value chain of the global HIV drugs market?
  • What are the key driving factors and challenges in the global HIV drugs market?
  • What is the structure of the global HIV drugs market and who are the key players?
  • What is the degree of competition in the global HIV drugs market?
  • How are HIV drugs manufactured?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Cipla Limited
  • Emcure
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Mylan
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global HIV Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Price Analysis
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Distribution Channel
5.6 Market Breakup by Region
5.7 Market Forecast
5.8 SWOT Analysis
5.8.1 Overview
5.8.2 Strengths
5.8.3 Weaknesses
5.8.4 Opportunities
5.8.5 Threats
5.9 Value Chain Analysis
5.9.1 Overview
5.9.2 Research and Development
5.9.3 Raw Material Procurement
5.9.4 Manufacturing
5.9.5 Marketing
5.9.6 Distribution
5.9.7 End-Use
5.10 Porters Five Forces Analysis
5.10.1 Overview
5.10.2 Bargaining Power of Buyers
5.10.3 Bargaining Power of Suppliers
5.10.4 Degree of Competition
5.10.5 Threat of New Entrants
5.10.6 Threat of Substitutes

6 Market Breakup by Drug Class
6.1 Nucleoside Reverse Transcriptase Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Multi-Class Combination Products
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Protease Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 HIV Integrase Strand Transfer Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Fusion Inhibitors and Others
6.7.1 Market Trends
6.7.2 Market Forecast

7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacies
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacies
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast

8 Market Breakup by Region
8.1 North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Latin America
8.5.1 Market Trends
8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process
9.1 Product Overview
9.2 Raw Material Requirements
9.3 Manufacturing Process
9.4 Key Success and Risk Factors

10 Competitive Landscape
10.1 Market Structure
10.2 Market Breakup by Key Players
10.3 Profiles of Key Players
10.3.1 Boehringer Ingelheim International GmbH
10.3.2 Merck & Co., Inc.
10.3.3 ViiV Healthcare
10.3.4 AbbVie
10.3.5 F. Hoffmann-La Roche Ltd.
10.3.6 Teva Pharmaceutical Industries Ltd.
10.3.7 Bristol-Myers Squibb
10.3.8 Gilead Sciences, Inc.
10.3.9 Johnson & Johnson
10.3.10 Cipla Limited
10.3.11 Daiichi Sankyo
10.3.12 Emcure
10.3.13 Hetero Drugs
10.3.14 Mylan

*List of Tables and Figures are available on enquiry
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Boehringer Ingelheim International GmbH
  • Merck & Co. Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan
Note: Product cover images may vary from those shown
Adroll
adroll